Innovent's Phase 3 Success Expands SYCUME's Potential In Thyroid Eye Disease
Innovent Biologics reported that its Phase 3 RESTORE-3 study of SYCUME (teprotumumab N01 injection) met primary endpoints in Chinese patients with inactive thyroid eye disease, showing significant reduction in eye protrusion and a favorable safety profile. The study involved 116 patients and achieved a 60.4% response rate. SYCUME is approved in China and added to the National Reimbursement Drug List in January 2026. The company's stock, 1801.HK, is currently trading at HKD 90.35, down 2.43%.
How this was made
The 30-second read
Why it matters
The trial's 60.4% proptosis response and 1.88 mm reduction exceed expectations, likely prompting analyst upgrades and increased investor interest.
Market read
Positive Phase 3 data provides a fresh catalyst for Innovent, potentially driving its HK‑listed shares higher and influencing the broader biotech sector.
What to watch
Potential regulatory hurdles outside China and competition from other TED treatments could temper gains.
Background
Innovent Biologics' SYCUME (teprotumumab) is already approved in China and listed on the HKEX under 1801.HK. The RESTORE-3 trial adds pivotal data for inactive thyroid eye disease.
Market effects
Strengthens the biotech sector's outlook on ophthalmology and autoimmune disease therapies.
May lift sentiment for Chinese-listed biotech stocks.
Adds confidence to investors in IGF-1R targeting drugs worldwide.
Counterpoint
If the market has already priced in the trial success, the stock may see limited upside.
Key entities
- companyInnovent Biologics
Chinese biotech developing SYCUME for thyroid eye disease.
- drugSYCUME (teprotumumab)
Recombinant antibody targeting IGF‑1R, approved in China.
